Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
4(67%)
Results Posted
50%(1 trials)

Phase Distribution

Ph not_applicable
1
17%
Ph phase_2
2
33%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(2)

Detailed Status

Recruiting4
Completed2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
4
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (66.7%)
N/A1 (33.3%)

Trials by Status

recruiting467%
completed233%

Recent Activity

4 active trials
Showing 5 of 6
recruitingphase_2

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

NCT06823375
completed

Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

NCT04862949
completed

Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy

NCT05197504
recruitingphase_2

Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion

NCT05992220
recruitingnot_applicable

TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT

NCT05984511
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06823375Phase 2

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Recruiting
NCT04862949

Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

Completed
NCT05197504

Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy

Completed
NCT05992220Phase 2

Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion

Recruiting
NCT05984511Not Applicable

TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Recruiting
NCT05173298

Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6